Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...

ver descrição completa

Detalhes bibliográficos
Principais autores: Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P
Formato: Conference item
Publicado em: 2014

Registros relacionados

Registros relacionados